Oral Ozempic and Label Expansions: Can Novo Nordisk Defend Against Pricing and Competition?

What happened

Novo Nordisk is betting on oral Ozempic and pediatric label expansions to counter slowing demand, pricing pressure, and rising competition in the GLP-1 market. However, the DeepValue report reveals that these moves come after U.S. share losses in 2025 for both Wegovy and Ozempic, with management guiding 2026 adjusted sales down -5% to -13% at CER. The key near-term catalyst is the expected $4.2 billion 340B revenue recognition in Q1 2026, which will boost reported revenue but does not address underlying net price erosion. Sustained improvement requires tangible proof that the newly launched Wegovy HD and oral Wegovy stabilize new-start share and that net pricing declines do not accelerate from 2025 levels. While valuation at 10.7x P/E already discounts significant headwinds, a re-rating depends on execution proof, not product announcements alone.

Implication

The near-term thesis hinges on two observable proof points: the 340B tailwind materializing in Q1 2026 and early prescription trends showing improved new-start share for the new formats. Without these, the stock risks becoming a value trap if net pricing erosion accelerates and share losses persist. Even at discounted multiples, the margin of safety is weak because earnings visibility is low amid an intensifying GLP-1 price war. The bull case requires volume growth to offset price compression, which is not yet confirmed. Therefore, investors should wait for the 90-day checkpoints outlined in the DeepValue report before adding exposure.

Thesis delta

The news piece provides no new data that alters the fundamental trajectory; it merely restates management's strategic response to known headwinds. Our thesis remains 'WAIT' as the next 3–6 months must deliver concrete evidence that the 340B release and product-line expansion are translating into share stabilization and net pricing deceleration.